StemCell Therapy

When you are traveling by vehicle to your destination, you should:

Once you reach your destination:

One of the most important aspects of managing Type 2 diabetes is for the patient to test their blood glucose level, usually twice a day. This could be more for some patients, depending on the care plan from their physician.

In an article in Healthline, Lisa Harris, CDE, RN at Rush University Medical Center in Chicago said that many patients with type 2 diabetes would likely benefit from testing more frequently. "Testing your blood sugar can be extremely informative for people when they're trying to prevent the need for further medication, like insulin," Harris said. "Even if they're only taking metformin, seeing for themselves how certain types of foods affect their blood sugar can have the biggest impact on motivating them to make changes in their diet."

In addition, when traveling, healthy eating tends to become more difficult to regularly sustain. People will usually eat out more and have less time to plan healthy meals or have fewer healthy options from which to choose. There's also less time to ensure proper nutrition and exercise which is important for managing diabetes.

"For people with diabetes, having their blood glucose readings sent to a provider is even more important when they travel because their diet might not be as healthy, eating times and patterns may shift, and other metabolic stressors related to traveling," said Dr. Bill Lewis, a leading telehealth consultant. "The iGlucose is the perfect traveling companion for people with diabetes so their test results are still being transmitted seamlessly to their provider."

Many of today's devices for at-home remote patient monitoring (RPM) rely on Bluetooth technology or Wi-fi paired to an app on a smartphone. These connections especially low-energy Bluetooth, can fail and may not reliably or securely deliver health data to providers.

The iGlucose from Smart Meter has proprietary cellular technology that utilizes the fast and secure 4/5G AT&T IoT network for reliable transmissions every time. With the cellular-enabled iGlucose, the measurement is sent immediately to the patient's provider with no extra steps required by the patient.

About Smart Meter, LLC

Now serving more than 100,000 patients, Smart Meter is the leading supplier of cellular-enabled virtual care technologies that include the iGlucose, iBloodPressure, iPulseOx, iScale, and SmartRPMcloud platform, as well as data, and services. Smart Meter's remote patient monitoring solutions are recognized as the standard for the RPM industry and are regarded for their high patient retention and satisfaction. The unique combination of reliable health data, patient-friendly devices, and platform integrations enable and enhance RPM, CCM, Employee Wellness, Population Health, and Telehealth programs for more than 300 RPM distribution partners across the United States. For more information, visitSmartMeterRPM.com

Smart Meter, LLC

Media Contact

5501 W. Waters Ave., Suite 401

Keith Tolbert

Tampa, FL 33602

[emailprotected]

813-773-4080

336-509-8024

SOURCE Smart Meter, LLC

The rest is here:
Diabetes Travel Essentials and Tips for the Approximately 21 Million Americans that Must Manage Their Diabetes While on Vacation - PR Newswire

News Release

Thursday, July 14, 2022

NIH-funded clinical trial finds that starting with a cheaper drug and switching to a more expensive drug as needed leads to good vision outcomes in diabetic macular edema.

Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug. The main complication of diabetic macular edema, fluid build-up in the retina that causes vision loss, is commonly treated with anti-vascular endothelial growth factor (VEGF) drugs.

The trial was funded by the National Eye Institute (NEI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both part of National Institutes of Health. Results of the trial, which examined a stepped regimen of anti-VEFG drugs Avastin (bevacizumab) and Eylea (aflibercept), were published today in the New England Journal of Medicine.

Our study showed that switching treatments when needed is a reasonable strategy, said Chirag Jhaveri, M.D., Austin Research Center for Retina, Texas, the lead study author. Insurance companies often require clinicians to start with the less expensive treatment, so we really wanted to see how a specific treatment strategy using this approach would affect patient care.

Diabetic macular edema is caused by diabetes-related alterations to retinal blood vessels. Symptoms include blurred vision. If untreated, vision loss can become permanent and progress to blindness. Retinal injections of anti-VEGF drugs can restore vision. The DRCR Retina Network previously showed that Avastin and Eylea improve visual acuity in people with diabetic macular edema. However, while Eylea is approved by the U.S. Food and Drug Administration to treat diabetic macular edema and results in better visual outcomes on average, off-label Avastin is much less expensive and is sometimes required by insurers as a first-line treatment.

The study enrolled 270 participants with diabetic macular edema, some of whom received treatments in both eyes. At enrollment, all had best-corrected visual acuity between 20/50 and 20/320. Half the study eyes were assigned to Eylea from the start, and half were assigned to start with Avastin. For participants who needed treatment in both eyes, each eye started treatment with a different drug. Participants received either Avastin or Eylea injections every four weeks for 24 weeks. If eyes assigned Avastin failed to reach the pre-set improvement benchmarks starting at 12 weeks, the eye was switched to Eylea.

After 24 weeks, physicians could taper down the frequency of injections as appropriate to maintain visual acuity. The study collected information about participants retinal structure and visual acuity for two years.

After two years, eyes in both groups had similar visual acuity outcomes, improving on average approximately three lines on an eye chart, compared to the trials start. In the Avastin group, 70% of eyes switched to Eylea during the study.

While most participants on Avastin eventually switched to Eylea, they still had improvement during those initial weeks, even if they didnt hit our pre-set benchmarks, said Adam Glassman of the Jaeb Center for Health Research and director of the DRCR Retina Network coordinating center. There are large cost disparities between these drugs, so differences in treatment strategies may have substantial cost implications.

Weve demonstrated here one method to managing a step treatment, where the outcomes are similar to the best existing treatment protocol with Eylea, said Jennifer Sun, M.D., M.P.H., of Joslin Diabetes Center and Harvard Medical School, Boston, and chair of diabetes initiatives for the DRCR Retina Network. Any time we can add to a clinicians toolbox, whether its a new medication or a new approach to using existing medications, as in this study, its a benefit for patients.

The study was supported by NEI (EY014231) and NIDDK through the Special Diabetes Program for Type 1 Diabetes Research. Clinical trial number NCT03321513.

NEI leads the federal governments research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Jhaveri CD, Glassman AR, Ferris FL, Liu D, Maguire MG, Allen JB, Baker CW, Browning D, Cunningham MA, Friedman SM, Jampol LM, Marcus DM, Martin DF, Preston CM, Stockdale CR, Sun JK, DRCR Retina Network. Aflibercept monotherapy versus bevacizumab first followed by aflibercept if needed for treatment of center-involved diabetic macular edema. NEJM. July 14, 2022.

###

Continued here:
A type of 'step therapy' is an effective strategy for diabetic eye disease - National Institutes of Health (.gov)

International Diabetes Federation (IDF) reports one in five Google searches for terms related to diabetes reveal inaccurate information about the condition and how to manage its complications, showing the lack of reliable diabetes education available for those who have or may have the condition.

The number of people living with diabetes continues to rise around the world, with the latest IDF estimatesindicating that one in nine adults will be affected by 2030. The necessity for reliable, accessible and accurate data on the condition can be a matter of life or death for people with serious cases of diabetes.

When diabetes is undetected and inadequately treated especially treated through home remedies which are reliant on misinformed articles on diabetes education people with diabetes are at higher risk of serious and life-threatening complications.

This is putting added strain on healthcare systems that, following two years of a global pandemic, are already struggling.

Out of 30 search results (the first results page for each search term), six links directed users to unverified information for different diabetes terms.

Terms including diabetes, how to manage diabetes and diabetes symptoms featured results and answers to questions from non-medical sources including Wikipedia, Amazon and Facty the last of which showed an article on home remedies for diabetes.

In one case, when searching for the term diabetes, users were shown an advert from an organisation that aims to wean people living with diabetes from insulin this can be extremely dangerous for those with type 1 diabetes, because if they experience an interruption in their supply of insulin, it can be potentially fatal.

Researchers of this data strongly advocate that decisions to reduce insulin treatment should be taken in close consultation with a qualified healthcare professional, preferably a specialist in diabetes.

According to IDF figures, an estimated 44.7% of adults living with diabetes (240 million people) across the world are undiagnosed with the overwhelming majority having type 2 diabetes.

Professor Andrew Boulton, IDF President, says: Many people now turn to Google and the internet for advice, so its worrying that misinformation about diabetes is still rife online.

With the prevalence of diabetes showing no signs of declining, ensuring that healthcare professionals are equipped to provide the best possible care and that people with diabetes can make informed decisions about their self-care is more important than ever. We need quality education today to help protect tomorrow.

IDF is committed to facilitating learning opportunities for all people concerned by diabetes, so their newonline platformhas been launched providing free interactive courses to help people with diabetes and their carers to understand and manage their condition.

The first course available provides an introduction to diabetes, explaining what it is, how it works and the common warning signs and risk factors.

For healthcare professionals, theIDF School of Diabetesoffers a selection of free and premium online courses that help them to keep up-to-date with various aspects of diabetes education, management and treatment.

Editor's Recommended Articles

Read more:
Diabetes education: one in five search results for diabetes lack reliable information - Open Access Government

Since 2005, talented performers ages 8-18 from across the St. Louis region come together every summer to form the Arch City Kids Theater Troupe (ACTT), producing a Broadway-style musical revue to raise money and awareness for JDRF (formerly the Juvenile Diabetes Research Foundation) in hopes of finding a cure for Type 1 diabetes.

As always, this year's production, Don't Stop Believin', is run entirely by kids, who cast, direct, choreograph and perform the show, donating all proceeds to JDRF. Don't Stop Believin' is directed this year by 18-year-old 2022 Lutheran South graduate, Gracie Maurer.

"ACTT is my favorite part of the summer," she says. "I've met lifelong friends and grown as a leader. I'm so excited to be directing the show this year!"

In 2021, ACTT's production Something About This Night raised $25,000, and over the years, with participation of more than 200 area kids, ACTT has given nearly $300,000 to JDRF.

Being a part of ACTT has become a fun and meaningful summer tradition for many young St. Louis performers, but for Assistant Director Natalie McAtee, singing and dancing in the show is only part of the appeal.

"Being able to raise money doing what I love for a disease that affects my friends is the highlight of my summer," said Natalie.

Gracie agrees.

"I am looking forward to raising money to turn Type 1 into Type None."

Don't Stop Believin', featuring songs from Broadway favorites like Rock of Ages, Hairspray, Legally Blonde, A Chorus Line, and Mamma Mia, runs August 5-7 at Ladue Horton Watkins High School. Tickets are free but donations are encouraged. Raffles and concessions are available at each show, and all proceeds go to JDRF.

For more information on ACTT: https://cloud.broadwayworld.com/rec/ticketclick.cfm?fromlink=2186141id=81&articlelink=http%3A%2F%2Fwww.archcitykids.org%2F?utm_source=BWW2022&utm_medium=referral&utm_campaign=article&utm_content=bottombuybutton1

Read more from the original source:
Arch City Kids Theater Troupe Fights Type 1 Diabetes With Its Annual Revue - Broadway World

DUBLIN--(BUSINESS WIRE)--The "Nutrigenomics Testing Market - Growth, Trends, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

The Global Nutrigenomics Testing market is expected to register a 13.3% of CAGR over the forecast period. The major factors for the market growth are increasing burden of lifestyle disorders and gaining popularity of personalized diet. Some of the lifestyle diseases include heart disease, and stroke, obesity and diabetes.

According to the World Health organization, cardiovascular diseases are one of the leading causes of death and around three-quarter of the deaths occur in low- and middle-income countries. Moreover, diet plays an influential role on the health with respect to the prevention of diseases and the overall quality of life. Thus, the nutrigenomics testing market growth is expected to propel.

Key Market Trends

Obesity Segment Expected to Exhibit Significant Market Growth

According to the factsheet of National Health Service, as of May 2020, about 20% of the children aged 6 years were obese in the United Kingdom. Childhood obesity is often associated with higher risk of premature death, disability in adulthood, and other risks such as difficulty in breathing, increased risk of fractures, hypertension, early markers of cardiovascular disease, insulin resistance and psychological effects.

Furthermore, obesity has been a major issue in high-income countries, however in recent years it has seen an upsurge in low- and middle-income countries. In 2018, approximately 40 million children that were under the age of five were obese worldwide, nearly half of this population was found to in Asia. Thus, the rising burden of obesity is expected to have a positive impact on the nutrigenomics testing market.

North America Expected to Hold a Significant Share in the Market

North America is expected to be a dominant region in the Nutrigenomics Testing market owing to rising burden of diseases due to sedentary lifestyle adoption. According to the Centre for Disease Control and Prevention, in 2017-18, the prevalence of obesity in the United States was found to be around 42.4% in adults. The prevalence of obesity was found to be more in women as compared to men. Furthermore, as per the data of Diabetes Research Institute, 2018, 34.2 million people in the United States had diabetes. Hence, a personalised dietary approach is gaining popularity for prevention and treatment of such diseases. Therefore, the aforementioned factors are expected to rise the demand for nutrigenomics testing market growth.

Competitive Landscape

Companies are taking initiatives to grow their presence in the market. In 2019, PT Kalbe Farma Tbk. launched Nutrigen-me panel that includes hormones, methylation, inflammation and antioxidants, plus sleep and lifestyle. Key players that are expected to be dominant in Nutrigenomics Testing market are Orig3n, DNA Life, Genus Health, LLC, Sanger Genomics Pvt. Ltd., The Gene Box, GX Sciences,Inc., Nutrigenomix, Cura Integrative Medicine and Holistic Health

Key Topics Covered

1 INTRODUCTION 1.1 Study Assumptions1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview4.2 Market Drivers4.2.1 Increasing Prevalence of Lifestyle Disorders4.2.2 Increasing Popularity for Personalized Diet4.3 Market Restraints4.3.1 Stringent Regulatory Framework4.4 Porter's Five Force Analysis4.4.1 Threat of New Entrants4.4.2 Bargaining Power of Buyers/Consumers4.4.3 Bargaining Power of Suppliers4.4.4 Threat of Substitute Products4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Application5.1.1 Obesity5.1.2 Diabetes5.1.3 Cancer5.1.4 Cardiovascular Disease5.2 Geography5.2.1 North America5.2.2 Europe5.2.3 Asia-Pacific5.2.4 Rest of the World

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles6.1.1 Cura Integrative Medicine6.1.2 DNA Life6.1.3 Genus Health, LLC6.1.4 GX Sciences, Inc.6.1.5 Holistic Health6.1.6 Nutrigenomix6.1.7 Orig3n6.1.8 Sanger Genomics Pvt. Ltd.6.1.9 The Gene Box

For more information about this report visit https://www.researchandmarkets.com/r/gp59f9

See the original post here:
Nutrigenomics Testing Industry Forecast to 2027 - Insights Into Obesity, Diabetes, Cancer, and Cardiovascular Disease Applications -...

Researchers have recently successfully treated Type 1 diabetes by transplanting insulin-producing pancreas cells into the patient.

University of Missouri scientists are partnering with Harvard and Georgia Tech to create a new diabetes treatment that involves transplanting insulin-producing pancreatic cells

Type 1 diabetes is estimated to affect around 1.8 million Americans. Although type 1 diabetes often develops in childhood or adolescence, it can occur in adulthood.

Despite active research, type 1 diabetes has no cure. Treatment methods include taking insulin, monitoring your diet, managing blood sugar levels, and exercising regularly. Scientists have also recently discovered a new treatment method that holds promise.

A group of researchers from the University of Missouri, Georgia Institute of Technology, and Harvard University has proved the successful use of a novel Type 1 diabetes treatment in a large animal model in a new study published in Science Advances on May 13th. Their method includes transferring insulin-producing pancreas cells, known as pancreatic islets, from a donor to a recipient without the need for long-term immunosuppressive medicines.

According to Haval Shirwan, a professor of child health and molecular microbiology and immunology at the MU School of Medicine and one of the studys primary authors, people with Type 1 diabetes immune system may malfunction, leading it to target itself.

The immune system is a tightly controlled defense mechanism that ensures the well-being of individuals in an environment full of infections, Shirwan said. Type 1 diabetes develops when the immune system misidentifies the insulin-producing cells in the pancreas as infections and destroys them. Normally, once a perceived danger or threat is eliminated, the immune systems command-and-control mechanism kicks in to eliminate any rogue cells. However, if this mechanism fails, diseases such as Type 1 diabetes can manifest.

Diabetes impairs the bodys ability to produce or utilize insulin, a hormone that aids in the regulation of blood sugar metabolism. People with Type 1 diabetes are unable to manage their blood sugar levels because they do not produce insulin. This lack of control may result in life-threatening problems including heart disease, kidney damage, and vision loss.

Shirwan and Esma Yolcu, a professor of child health and molecular microbiology and immunology at the MU School of Medicine, have spent the last two decades targeting an apoptosis mechanism that prevents rogue immune cells from causing diabetes or rejection of transplanted pancreatic islets by attaching a molecule called FasL to the islets surface.

A type of apoptosis occurs when a molecule called FasL interacts with another molecule called Fas on rogue immune cells, and it causes them to die, said Yolcu, one of the studys first authors. Therefore, our team pioneered a technology that enabled the production of a novel form of FasL and its presentation on transplanted pancreatic islet cells or microgels to prevent being rejected by rogue cells. Following insulin-producing pancreatic islet cell transplantation, rogue cells mobilize to the graft for destruction but are eliminated by FasL engaging Fas on their surface.

Haval Shirwan and Esma Yolcu work in their lab at the Roy Blunt NextGen Precision Health building. Credit: University of Missouri

One advantage of this new method is the opportunity to potentially forgo a lifetime of taking immunosuppressive drugs, which counteract the immune systems ability to seek and destroy a foreign object when introduced into the body, such as an organ, or in this case, cell, transplant.

The major problem with immunosuppressive drugs is that they are not specific, so they can have a lot of adverse effects, such as high instances of developing cancer, Shirwan said. So, using our technology, we found a way that we can modulate or train the immune system to accept, and not reject, these transplanted cells.

Their method utilizes technology included in a U.S. patent filed by the University of Louisville and Georgia Tech and has since been licensed by a commercial company with plans to pursue FDA approval for human testing. To develop the commercial product, the MU researchers collaborated with Andres Garca and the team at Georgia Tech to attach FasL to the surface of microgels with proof of efficacy in a small animal model. Then, they joined with Jim Markmann and Ji Lei from Harvard to assess the efficacy of the FasL-microgel technology in a large animal model, which is published in this study.

Haval Shirwan looks at a sample through a microscope in his lab at the Roy Blunt NextGen Precision Health building. Credit: University of Missouri

This study represents a significant milestone in the process of bench-to-bedside research, or how laboratory results are directly incorporated into use by patients in order to help treat different diseases and disorders, a hallmark of MUs most ambitious research initiative, the NextGen Precision Health initiative.

Highlighting the promise of personalized health care and the impact of large-scale interdisciplinary collaboration, the NextGen Precision Health initiative is bringing together innovators like Shirwan and Yolcu from across MU and the UM Systems three other research universities in pursuit of life-changing precision health advancements. Its a collaborative effort to leverage the research strengths of MU toward a better future for the health of Missourians and beyond. The Roy Blunt NextGen Precision Health building at MU anchors the overall initiative and expands collaboration between researchers, clinicians, and industry partners in the state-of-the-art research facility.

I think by being at the right institution with access to a great facility like the Roy Blunt NextGen Precision Health building, will allow us to build on our existing findings and take the necessary steps to further our research, and make the necessary improvements, faster, Yolcu said.

Haval Shirwan and Esma Yolcu. Credit: University of Missouri

Shirwan and Yolcu, who joined the faculty at MU in the spring of 2020, are part of the first group of researchers to begin working in the NextGen Precision Health building, and after working at MU for nearly two years they are now among the first researchers from NextGen to have a research paper accepted and published in a high-impact, peer-reviewed academic journal.

Reference: FasL microgels induce immune acceptance of islet allografts in nonhuman primates by Ji Lei, Mara M. Coronel, Esma S. Yolcu, Hongping Deng, Orlando Grimany-Nuno, Michael D. Hunckler, Vahap Ulker, Zhihong Yang, Kang M. Lee, Alexander Zhang, Hao Luo, Cole W. Peters, Zhongliang Zou, Tao Chen, Zhenjuan Wang, Colleen S. McCoy, Ivy A. Rosales, James F. Markmann, Haval Shirwan and Andrs J. Garca, 13 May 2022, Science Advances.DOI: 10.1126/sciadv.abm9881

Funding was provided by grants from the Juvenile Diabetes Research Foundation (2-SRA-2016-271-S-B) and the National Institutes of Health (U01 AI132817) as well as a Juvenile Diabetes Research Foundation Post-Doctoral Fellowship and a National Science Foundation Graduate Research Fellowship. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

The studys authors would also like to acknowledge Jessica Weaver, Lisa Kojima, Haley Tector, Kevin Deng, Rudy Matheson, and Nikolaos Serifis for their technical contributions.

Potential conflicts of interest are also noted. Three of the studys authors, Garca, Shirwan, and Yolcu, are inventors on a U.S. patent application filed by the University of Louisville and the Georgia Tech Research Corporation (16/492441, filed Feb. 13, 2020). In addition, Garca and Shirwan are co-founders of iTolerance, and Garca, Shirwan, and Markmann serve on the scientific advisory board for iTolerance.

See the original post:
Harvard Scientists Have Developed a Revolutionary New Treatment for Diabetes - SciTechDaily

Upon receiving a diagnosis of type 1 diabetes (T1D), many people have the same reaction: But why me?

Some people have T1D that runs in their family, while others have no idea how or why they received a diagnosis. Often, to their frustration, those questions go unanswered.

But some people can seemingly link their T1D diagnosis to a previous virus they had endured directly before their onset of T1D.

This makes sense, as T1D is an autoimmune disease. This means your bodys own immune system mistakenly attacks its own insulin-producing beta cells. Although scientists dont know the exact causes or reasons why T1D develops, some researchers believe this haywire immune system reaction is the result of a virus triggering your bodys defense system to go into overdrive.

Viruses are now one main hypothesis of the cause of T1D. In particular, coxsackievirus is on the rise in those with newly diagnosed T1D. That has led some to wonder if theres a direct correlation between this virus, or any virus for that matter.

Read on for more about coxsackievirus, how it materializes in people, and what research has to say about its potential for causing T1D.

Coxsackievirus is a virus thats part of the enterovirus family, which lives in the human digestive tract. This enterovirus family also includes polioviruses, hand, foot, and mouth disease (HFMD), and hepatitis A virus.

This virus spreads easily from person to person, usually through human touch or on surfaces contaminated with feces. The virus can live for several days without a host, making it extremely easy to spread.

When theres a coxsackievirus outbreak, its most likely to affect babies and children younger than 5 years old, as its easily spreadable in places such as daycare centers, schools, and summer camps. Youre most contagious the first week that youre sick, and the best preventive mechanism is hand washing.

Usually, infection with this virus results in these mild flu-like symptoms initially:

Many people have no symptoms at all, and most people recover without treatment. But sometimes the virus can trigger more serious conditions or reactions, such as with HFMD, where a blister-like rash may appear on your hands or feet or in your mouth.

Theres no specific treatment for this virus, and antibiotics dont help with viral infections.

When a virus invades your body, your immune system produces antibodies to fight off that infection. T cells are in charge of developing antibodies as well as fighting off the virus.

But if the virus has some of the same antigens (or substances that cause your immune system to produce antibodies against them) as your bodys own pancreatic beta cells (in the case of T1D), the T cells sometimes start attacking your bodys own beta cells.

This miscommunication is common and results in autoimmune diseases like T1D. Once all the beta cells have been destroyed, T1D is developed and diagnosed. This is why people sometimes receive a diagnosis of T1D a few months after recovering from a bad virus.

But it can sometimes take more than a year for your bodys T cells to destroy the majority of your beta cells (sometimes people experience the honeymoon phase of diabetes, where their pancreas is still producing a minimal amount of insulin), but that original viral infection is hypothesized to be a trigger in the development of T1D.

Not every virus can trigger this reaction ending in T1D. The virus must have antigens that are similar enough to the antigens in pancreatic beta cells. Those viruses include:

Theres mounting evidence that the coronavirus disease 19 (severe acute respiratory syndrome coronavirus 2) pandemic is causing a tidal wave of new T1D diagnoses to be received by both children and adults. But the full repercussions of the pandemic are yet to be seen.

A 2018 study showed that kids exposed to enteroviruses are more likely to develop T1D.

The Environmental Determinants of Diabetes in the Young study found, through nearly 8,000 stool samples of children in the United States and Europe, an association between an exposure and infection with coxsackievirus. This study followed participants for 30 days or longer and focused on the development of an autoimmune reaction that can lead to a T1D diagnosis.

In a Finland-based study, researchers tested more than 1,600 stool samples from 129 children who had recently developed T1D. They also tested 282 children without diabetes for enterovirus RNA, a marker of previous exposure to infection.

Researchers also found 60 percent of the control group showed signs of prior infection (without diabetes), compared with 75 percent of the group with T1D.

They also found that children who developed T1D were exposed to the virus more than a year before their diabetes was diagnosed. Taking this lag time of viral infection to T1D diagnosis into account, the researchers believed that children with diabetes are exposed to three times more enteroviruses than children without diabetes.

Viral infections arent the only hypothesized cause of T1D, but research is homing in on viruses as a common trigger. Studies have shown that even if pregnant people are exposed to enteroviruses, such as coxsackievirus, theyre more likely to give birth to children who eventually develop T1D.

Researchers arent exactly sure what the precise cause of T1D is, and the virus hypothesis is just one theory. Many people believe that T1D is caused by a mix of genetic and environmental factors and that the disease may just be finally triggered by catching a virus such as coxsackievirus or another enterovirus.

While preventing viral spread is always important, even if all enteroviruses were prevented, T1D wouldnt be prevented in everyone, but it would probably make a big difference.

Researchers are hopeful with new trials showing vaccines against enteroviruses could potentially prevent many new diagnoses of T1D, but they wont prevent all people from receiving diagnoses of course.

While theres no vaccine to prevent T1D, Dr. Denise Faustman, Director of the Massachusetts General Hospital Immunobiology Laboratory, is working on that research front. Her work focuses on the bacillus Calmette-Gurin (BCG) vaccine, traditionally used to prevent tuberculosis, and how it can help people with T1D. Specifically, this century-old BCG vaccine may boost a substance called tumor necrosis factor, which eliminates T cells and helps develop more beneficial cells called regulatory T cells.

If you have diabetes, this could help improve your blood sugar and A1C levels while lowering your insulin requirements even years after your initial vaccination. That research is expected to continue for at least several more years beyond 2022.

The exact causes of T1D arent known. But research shows enteroviruses, and in particular coxsackievirus, may play a part in the development of this autoimmune condition. Most researchers believe it to be a mix of both environmental and genetic factors, with perhaps a viral infection trigger. Research remains ongoing, and the development of a coxsackievirus vaccine could go a long way in preventing people worldwide from receiving diagnoses of T1D in the future.

Read this article:
Do Viruses and Coxsackievirus Cause Type 1 Diabetes? - Healthline

While managing diabetes can be challenging, you can still do the things you enjoy in life. (Getty Images)

This diabetes week, and every week, it's important that just because diabetes is a hidden condition, it doesn't get ignored.

One in 14 of us live with the condition, while even more care for a loved one who does, according to Diabetes UK.

So, whether you might suspect you have diabetes, support someone else with it, are recently diagnosed, or just want to learn more about the condition, here are the basics of what there is to know.

Read more: Kate Moss' daughter Lila proudly sports blood glucose monitor in Fendace campaign

If you're diagnosed with diabetes, a medical professional will explain all you need to know about managing it. (Getty Images)

Diabetes is a lifelong condition that causes a person's blood glucose levels (also called blood sugar) to become too high, according to the NHS. There are two main types, Type 1 and Type 2, though some can also get Gestational diabetes.

Pre-diabetes is when people have blood glucose levels above the normal range, but are not high enough to be diagnosed with the condition itself. But it's important to keep in mind that if your levels are higher than most, your risk of developing full-scale diabetes is increased.

Getting diabetes diagnosed early is key to prevent it from getting progressively worse, which can happen if left untreated.

The finger-prick test has long been used to manage diabetes, though there are now more advanced methods. (Getty Images)

Type 1 diabetes is where the body's immune system attacks and destroys the cells that produce insulin. You need to take insulin every day to keep your blood glucose levels under control. Type 1 is not linked with age, being overweight or lifestyle factors, whereas Type 2 is.

The NHS website says you should see a GP if you have symptoms of type 1, which include:

feeling very thirsty

peeing more than usual, particularly at night

feeling very tired

losing weight without trying

thrush that keeps coming back

blurred vision

cuts and grazes that are not healing

fruity-smelling breath

Type 1 signs and symptoms can come on quickly, particularly in children.

To get tested, your GP will do a urine test and might also check your blood glucose level. If they suspect you have diabetes, you'll be advised to go to hospital immediately for further assessments, where you will stay until you get results (usually the same day).

Story continues

If you are diagnosed, then a specialist diabetes nurse will explain everything you need to know about the condition, including how to manage it, test your own blood glucose and how to inject insulin.

Finger-prick tests have long been used to manage diabetes, though you can now check your glucose levels at any time with a continuous glucose monitor (CGM) or flash monitor.

This involves using a sensor, a small device you attach to your arm or tummy that senses how much glucose is in the 'interstitial' fluid under your skin, and a reader or receiver, which shows the results (you can also read them on your smartphone). Some types have optional alarms to alert you if your levels go too low or high.

Read more: What types of dementia are there? Signs and symptoms to see your GP about

While interstitial fluid readings have made many people living with diabetes' lives much easier, it's important to remember they're a few minutes behind your blood glucose levels. This means you'll still need to do finger-prick checks every now and then, particularly when you drive or have a hypoglycaemia (when your blood glucose level is too low), as this tells you what your level is at that moment.

Although being diagnosed with and managing diabetes can be difficult at times, you can still do the things you enjoy. This useful NHS guide on being newly diagnosed provides information to help, including how to recognise and treat a hypo, useful websites, online courses and more.

Do you have the symptoms of diabetes? (Getty Images)

Type 2 diabetes is where the body does not produce enough insulin, or the body's cells do not react to insulin. It is far more common than type 1, with around 90% of all adults in the UK with diabetes living with it.

It can be linked to being overweight or inactive, or having a family history of type 2 diabetes. You're also more at risk of this type of diabetes if you're over 40 (or 25 for south Asian people), have a close relative with diabetes, are overweight or obese, are of Asian, African-Caribbean or black African heritage.

Many people can have type 2 diabetes without realising, because symptoms don't always make you feel unwell.

The NHS website says you should see a GP if you have symptoms of type 2 (similar to type 1), which include:

peeing more than usual, particularly at night

feeling thirsty all the time

feeling very tired

losing weight without trying to

itching around your penis or vagina, or repeatedly getting thrush

cuts or wounds taking longer to heal

blurred vision

You should also see a GP if you're worried you may have a higher risk of getting type 2. You check your risk here.

Some people find checking blood glucose levels with a continuous glucose monitor (CGM) or flash monitor easier. (Getty Images)

Gestational diabetes can also occur during pregnancy, when some women have such high levels of blood glucose that their body is unable to produce enough insulin to absorb it all.

While it can happen at any stage of pregnancy, it is more common in the second or third trimester. It usually disappears after giving birth.

That said, it can cause problems for you and your baby during pregnancy and after birth, but the risks can be reduced if the condition is detected early and well managed.

Read more: How to stay safe in hot weather: Top tips to avoid heatstroke this summer

With the causes of Type 1 and Type 2 different, a doctor will explain how management differs. (Getty Images)

Elaborating on the above, the amount of sugar in the blood is controlled by a hormone called insulin, which is produced by the pancreas (a gland behind the stomach), the NHS explains.

Normally, when food is digested and enters your bloodstream, insulin moves glucose out of the blood and into cells, where it's broken down to produce energy.

However, if you have diabetes, your body is unable to break down glucose into energy because there's either not enough insulin to move it, or the insulin produced doesn't work properly.

While there are no lifestyle changes you can make to lower your risk of of type 1 diabetes, you can help manage type 2 diabetes through healthy eating, regular exercise and achieving a healthy body weight.

There's nothing you can't eat if you have type 2 diabetes, but the NHS suggests limiting certain foods. You should eat a wide range of food (fruit, veg and some starchy foods like pasta), keep sugar, fat and salt to a minimum, and make sure you eat breakfast, lunch and dinner every day do not skip meals.

If you need to change your diet, it might be easier to make small changes every week, it adds.

Altering your lifestyle in small ways can go a long way to reduce your risk of type 2 diabetes. (Getty Images)

Diet, exercise and a healthy lifestyle can also help to reduce the likelihood of getting type 2 diabetes, with more than 13.6 million people in the UK at an increased risk.

"Fortunately even in people with a strong family history of diabetes making positive lifestyle choices can help avoid diabetes altogether," says Dr Sundhya Raman, Medical Doctor and Lifestyle Medicine Physician, Plant Based Health Professionals.

In terms of diet, Ruman says we should try to avoid "processed foods, sugar-sweetened foods and drinks, saturated fats (found in animal source foods and tropical oils), and red and processed meats".

On exercise, she explains it is never too late to start, and build up gradually. "Most people think they need to be quite fit before they get a benefit from exercising, but in fact going from doing nothing to doing something is when the biggest gains are achieved."

It seems sleep is very important too. "We should all be aiming for 7-8 hours of sleep a night, and people who chronically sleep less than this amount raise their risk of diabetes by about 30%," she says.

"When we dont get enough sleep we also have dysregulated levels of our hunger and satiety hormones so are more likely to eat more, particularly foods that are not good for us and make us put on weight, so sleep should also be a priority."

Of all lifestyle factors, Raman says poor diet is the biggest risk. "In studies, the dietary group who have the lowest rates of diabetes are whole-food plant based. They are also the group that tend to have the lowest BMI compared with any other dietary group such as pescatarians or omnivores, and we know that a high BMI is one of the most significant risk factors [for having diabetes].

Some believe food is medicine when it comes to reducing your risk of diabetes, or even reversing it. (Getty Images)

Plant-based diets can reduce the risk of type 2 diabetes by up to 60%, according to Plant Based Health Professionals. But how does this work?

Soluble fibre, she explains helps us to feel full and maintain a healthy weight, release the carbohydrate from our food into our bloodstream slowly, and is the superfood for bugs that live in our colon, of which a healthy balance of can lower the risk of diabetes.

"Plant foods are also full of antioxidants that help reduce the damage that happens to our cells from everyday activities, as well as some of the more damaging things we do such as eating the wrong kinds of foods or sitting for prolonged periods," Ruman adds. "We also know that some of the compounds in plant foods switch on genes that optimise our metabolism.

She also says wholegrains are the food type that have been shown in studies to be particularly important in reducing diabetes and cardiovascular risk. However, in the UK we don't have specific guidelines on how many portions to eat, or any legislation on what can be termed a wholegrain, so people can eat processed foods with few wholegrains, thinking they are improving their health, or think they're bad for people with diabetes, as are often grouped under carbs.

Read more: Earth Day 2022: 7 ways to reduce your carbon 'foodprint' to save the planet

"I would recommend 3 portions of wholegrains per day, ideally as unprocessed as possible." She also reccomends a variety of fruit and vegetables, as well as variety in your nuts, seeds, wholegrains, lentils, legumes, herbs and spices, while prioritising plant sources of proteins over those from animal sources.

In some cases, plant-based are also effective at reversing Type 2 diabetes, effective at reversing insulin resistance, which is thought to happen fat gets stored in our muscle and liver, and damages cells."One of the ways in which a whole-food plant-based diet is incredibly beneficial is that people tend to lose weight when they follow this dietary pattern, and we know that weight loss can reverse diabetes."

Make sure you consult a doctor before making any big dietary changes.

For more information, visit the NHS' website on diabetes, or seek support from Diabetes UK on 0345123 2399.

Watch: Diabetes drug leads to significant weight loss in those with obesity, study finds

The rest is here:
Diabetes Week: Types 1 and 2 symptoms, causes and prevention - Yahoo Entertainment

MadameNoire Featured Video

Source: Adene Sanchez / Getty

Great sex, anecdotally, is uninhibited and free of worry. Its a time to put aside the usual responsibilities that plague you and just enjoy the moment. But diabetes and sex have a slightly complicated relationship. For people with type 1 diabetes, fully detaching from responsibilities isnt an option in fact, it can be dangerous. Its no surprise then that a study conducted by Oxford University professors found that 62 percent of people with diabetes say their condition has negatively impacted their relationships with their partners.

Having to think about your type 1 diabetes during intimacy can be agitating and even disheartening. But its important to remember that many adults have to do some planning before sex. Some men have to take pills for erectile dysfunction. Tons of women need lubricant due to a hormonal imbalance. And lets not forget about all of the people who need a lumbar support pillow for missionary. Everyone deserves to enjoy sex. Heres what you need to know about having safe and enjoyable sex, when you have type 1 diabetes.

Source: Andriy Onufriyenko / Getty

There are several reasons that those with type 1 diabetes cant explore the Kama Sutra without some planning. First off, a lot of sex depending on how you go about it counts as a workout. It gets your blood pumping, it gets you sweating and, like any exercise, it impacts blood sugar levels. While people who dont have diabetes can handle these blood sugar fluctuations fairly well, people with diabetes need to be careful.

Next, theres the added factor of booze. Its common for people to enjoy a drink (or a few) before having sex. Alcohol helps loosen those inhibitions and make you feel relaxed. But, if you drink too much or dont stick to diabetic-friendly cocktails, your blood sugar levels can go on a roller coaster.

The ways sex plays on blood sugar levels dont stop there. Even if you stay sober for sex, the mere excitement of being with a partner can impact blood sugar levels. So, while its frustrating, the fact that sex affects blood sugar levels cannot be ignored.

Source: kali9 / Getty

If you know that your night will likely end in sex, take steps to put your blood sugar levels in a healthy range by the time intimacy occurs. This means being careful about what you eat, using insulin when necessary and even monitoring other physical activity throughout the day. If your sessions in the sack are particularly active, then you might need to skip your afternoon workout. You dont want to put yourself at risk of low blood sugar mid-coitus due to over-exertion.

Source: NurPhoto / Getty

Even if you eat right and monitor your blood sugar levels, things can still go awry after a few rounds with your partner. Be sure to keep snacks on the nightstand so you can reach for them if you feel your blood sugar levels dropping. Better yet, incorporate sexy foods like strawberries or chocolate sauce (sugar-free if necessary) into sex so it doesnt feel like snack time is putting a pause on the fun.

Source: FG Trade / Getty

Sex is always better when you can communicate with your partner. That is true about every topic, from what positions work for you to managing your blood sugar levels. Notify your partner in advance that sex can impact your blood sugar, and that you might need to pause during the activities to have a snack or take insulin. Additionally, if you can tell tonight is just not a good night to do the deed, speak up. Pushing yourself through sex when your blood sugar levels are off can be dangerous.

Source: Andriy Onufriyenko / Getty

If you wear an insulin pump or a blood glucose monitor, you might be tempted to remove this during sex. Some diabetics struggle to feel sexy when wearing these devices (and nothing else) in front of a partner. First off, theres no shame in wearing a device that keeps you alive and enables you to live the way that you enjoy. However, there are some practicalities to consider, like the fact that these devices can get tangled or fall off during sex.

If you want to remove your device during sex, make sure to get your blood sugar levels in a healthy range right before the activities. And then put the device back on immediately after sex. If your blood sugar levels arent stable enough for device removal, get creative and choose positions that let you keep the device on. Again, communication is key here.

Source: Andreas Stamm / Getty

It is important to know that type 1 diabetes can impact sexual function in many ways. For women, high blood sugar can lead to vaginal dryness, according to the Journal of Natural Science, Biology and Medicine. For men, blood sugar issues can cause erectile dysfunction. And people of all genders can experience mood swings and a low libido in connection to type 1 diabetes.

While there are practical fixes for vaginal dryness like finding a lubricant you love the other symptoms can be more complicated to treat. If you are struggling with any of these issues, first off, know that its common for people with type 1 diabetes and is nothing to be embarrassed about. Then talk to your doctor about the best way to treat the problem.

Having type 1 diabetes doesnt have to mean the end of a fun, playful and even erotic sex life. It simply means you have to do a little extra planning. But when you have a partner with whom you can communicate openly, that planning wont feel like a burden. And when you know your body will be safe and taken care of, then you can let go and be in the moment.

RELATED CONTENT:7 Things Doctors Wish Black Women Knew About Diabetes

Go here to see the original:
Diabetes And Sex: Have Safe Sex While Managing Diabetes - MadameNoire

Wilmington, Delaware, United States: According to Transparency Market Researchs latest report on the global diabetes devices market for the historical period 20172018 and forecast period 20192027, increase in prevalence of diabetes, and increase in adoption of insulin pumps among type 1 diabetes patients are projected to drive the global diabetes devices market during the forecast period.

According to the report, the global diabetes devices market was valued at US$ 41.8 Bn in 2018 and is anticipated to expand at a CAGR of 6.4% from 2019 to 2027.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14

Increase in Prevalence of Diabetes Expected to Drive Global Diabetes Devices Market: Key Drivers

Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14

Increase in Adoption of Insulin Pump among Type 1 Diabetes Patients Boost Market Growth

Request for Analysis of COVID19 Impact on Diabetes Devices Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=14

Threat of Alternative Therapies for Diabetes to Hamper Market

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=14

Global Diabetes Devices Market: Competitive Landscape

This report profiles major players in the global diabetes devices market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global diabetes devices market is highly fragmented, with the presence of a number of international as well as regional players

Leading players operating in the global diabetes devices market are

More Trending Reports by Transparency Market Research

Audiological Devices Market: https://www.transparencymarketresearch.com/audiological-devices-market.html

Eye Care Surgical Devices Market: https://www.transparencymarketresearch.com/eye-care-surgical-devices-market.html

Breast Reconstruction Market: https://www.transparencymarketresearch.com/breast-reconstruction-market.html

Radiation Therapy Market: https://www.transparencymarketresearch.com/radiation-therapy-market.html

Thyroid Function Test Market: https://www.transparencymarketresearch.com/thyroid-functioning-tests-market.html

Roadside Drug Testing Devices Market: https://www.transparencymarketresearch.com/us-roadside-drug-testing-devices-market.html

Smart Fertility Tracker Market: https://www.transparencymarketresearch.com/smart-fertility-tracker-market.html

Radiation Therapy Market: https://www.transparencymarketresearch.com/radiation-therapy-market.html

About Us

Transparency Market Research is a global market intelligence company providing market research reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Rohit Bhisey

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

The rest is here:
Diabetes Devices Market to Expand at the CAGR of 6.4% from 2019 to 2027, Increase in Prevalence of Diabetes Expected to Drive Global Market - BioSpace

If you live with diabetes, you may be aware that having the condition and its complications may put you at greater risk of developing anemia. But how are the two conditions related and what does this mean for you?

This article will investigate the relationship between diabetes and anemia, and what you should know if you have diabetes-related complications impacting your life.

According to the National Heart, Lung, and Blood Institute, Anemia is a condition in which the blood doesnt have enough healthy red blood cells to function properly. This leads to reduced oxygen flow to the bodys organs.

There are more than 3 million cases of anemia diagnosed in the United States every year, making this a very common condition.

You may experience the following symptoms:

Its important to note that some anemia symptoms are similar to symptoms of high blood sugar, including dizziness, lightheadedness, extreme fatigue, rapid heart rate, and headache.

Check your blood sugar often to make sure youre not confusing high blood sugar for suspected anemia. If your symptoms continue for a few days or weeks without high blood sugar numbers or ketones, call a healthcare professional to get checked for anemia.

Diabetes doesnt cause anemia and anemia doesnt cause diabetes. The two conditions are related, though.

Up to 25 percent of Americans with type 2 diabetes also have anemia. So its relatively common for people with diabetes, and especially diabetes-related complications, to also develop anemia.

However, if you have one condition or the other, you wont automatically develop the other condition.

As seen in this 2004 study, Anemia is a common complication of people with diabetes who develop chronic kidney disease because damaged or failing kidneys dont produce a hormone called erythropoietin (EPO), which signals to the bone marrow that the body needs more red blood cells to function.

Early stages of kidney disease (nephropathy) may be asymptomatic, but if youre diagnosed with anemia and you have diabetes, it might be a sign that your kidneys arent working properly.

People with diabetes are also more likely to have inflamed blood vessels. This prevents the bone marrow from even receiving the EPO signal to create more red blood cells to begin with. That makes anemia a more likely result.

Additionally, if you have existing anemia and are then diagnosed with diabetes, it may make you more likely to develop diabetes-related complications, such as retinopathy and neuropathy (eye and nerve damage).

A lack of healthy red blood cells can additionally worsen kidney, heart, and artery health, systems that are already taxed with a life lived with diabetes.

Certain diabetes medications can decrease your levels of the protein hemoglobin, which is needed to carry oxygen through the blood. These diabetes medications can increase your risk of developing anemia:

Since blood loss is also a significant contributor to the development of anemia, if you have diabetes and are on kidney dialysis, you may want to talk with your healthcare team about your increased risk of anemia as well.

Anemia can affect blood sugar levels in several ways.

One 2010 study found that anemia produced false high blood sugar levels on glucose meters, leading to dangerous hypoglycemia events after people overtreat that false high blood sugar.

As shown in a 2014 study, theres a direct link between anemia caused by iron deficiency and higher amounts of glucose in the blood. A 2017 review of several studies found that in people both with and without diabetes, iron-deficiency anemia was correlated with increased A1C numbers.

This resulted from more glucose molecules sticking to fewer red blood cells. After iron-replacement therapy, HbA1c levels in the studies participants decreased.

If you receive an anemia diagnosis and you live with diabetes, there are many excellent treatment options.

Treatment will depend on the underlying cause of the condition, but may include supplementation with iron and/or vitamin B.

If your anemia is caused by blood loss, a blood transfusion may be necessary. If your bodys blood production is reduced, medications to improve blood formation may be prescribed.

Diabetes and anemia are closely related, though neither directly causes the other condition.

Diabetes-related complications such as kidney disease or failure and inflamed blood vessels may contribute to anemia. Certain diabetes medications can also increase the likelihood of developing anemia. Anemia may also make diabetes management more challenging, with higher A1C results, false high blood sugars, and a potential risk of worsening organ health leading to future diabetes complications.

Still, anemia is very treatable with supplementation, dietary or medication changes.

Visit link:
Anemia and Diabetes: What You Should Know - Healthline

Patient education is a component of prevention of progression of kidney disease. Paul Flynn and colleagues at SUNY Downstate Health Science University, Brooklyn, New York, interviewed patients with end-stage kidney disease (ESKD) secondary to diabetic kidney disease to determine their knowledge of their disease and how it relates to chronic kidney disease (CKD).

Results of the interviews were reported during a poster session at the NKF 2022 Spring Clinical Meetings. The poster was titled Knowledge Gaps Regarding Chronic Kidney Disease and Diabetes in a Population of Inner-City Dialysis Patients.

The survey was administered to 15 randomly selected dialysis patients with diabetes. The survey included questions about patient knowledge about diabetes and kidney disease at the time of diagnosis. The researchers also collected demographic information.

Mean age of the respondents was 64.3 years, 53% (n=8) were male, 47% (n=7) had less than a college education, 89% (n=8/9) made less than $40,000 per year. Mean time with diabetes was 29.0 years. Eight of 13 patients saw an endocrinologist, and four reported most recent hemoglobin A1c (HbA1c) >10%. Twelve of 13 respondents reported they had no knowledge of what CKD was and 10 of 13 did not know at the time of their diabetes diagnosis that diabetes could cause kidney disease.

There was no correlation between knowledge and age, education, length of time with diabetes, income, or sex. Patients who were older were lesse likely to see an endocrinologist (r=0.64; P=.019), checked their glucose less frequently (r=0.71; P=.006), and did not check after eating (r=0.62; P=.023). Thirteen of 14 patients said they did know what HbA1c was, 11 of 14 knew that insulin decreases blood glucose levels, 12 of 14 knew that a person with type 2 diabetes had increased blood glucose, and ten of 14 patients knew that HbA1c should be checked every 3 months. Six of 13 patients did not know what a nephrologist is and nine of 13 did not know how kidney function is measured.

In summary, the authors said, In our population of inner-city dialysis patients with diabetes mellitus: (1) The majority were knowledgeable about diabetes, although older patients were less likely to see an endocrinologist and check their blood sugar frequently or after eating. (2) The majority of patients had no knowledge of kidney disease and did not know that diabetes could cause kidney disease at the time of their diagnosis. (3) Almost half of patients currently did not know what a nephrologist was and did not know how kidney function is measured. (4) An early education program for our underserved population regarding the relationship between kidney disease and diabetes should be designed in the hopes of delaying progression to ESKD.

Source: Flynn P, Sherman B, Wei L, et al. Knowledge gaps regarding chronic kidney disease and diabetes in a population of inner-city dialysis patients. Abstract of a poster presented at the National Kidney Foundation 2022 Spring Clinical Meetings (Abstract 273), Boston, Massachusetts, April 6-10, 2022.

Here is the original post:
Patient Knowledge of Diabetes and CKD in an Inner-City Population - DocWire News

BASEL, Switzerland, June 16, 2022 /PRNewswire/ --Ascensia Diabetes Care, a global diabetes care company,maker of CONTOURblood glucose monitoring (BGM) system portfolio and distributor of Eversense Continuous Glucose Monitoring (CGM) Systems, announces that its partner Senseonics Holdings, Inc. has received CE Mark approval for the Eversense E3 Continuous Glucose Monitoring (CGM) System, clearing the way for its use in European Union (EU) member countries. Ascensia plans to make the next-generation system, which can be used for up to 6 months, available to patients in certain European markets from the third quarter of 2022.

The fully implantable, long-term Eversense E3 CGM System has been designed to deliver key improvements on the currently available Eversense XL CGM System, whilst building on the unique benefits that European users already experience. The next-generation system offers exceptional accuracy and long-term sensor wear, alongside reduced frequency of calibration and significantly enhanced sensor survivability. Unlike the XL System, the new E3 System has also been approved for non-adjunctive use, meaning that it can inform insulin treatment decisions without confirmation of glucose levels from fingerstick testing. Both Eversense XL and Eversense E3 are approved for use up to 6 months, making them the longest lasting CGM sensors available. This gives people with diabetes freedom from the burdens associated with other available CGM systems, such as weekly or bi-weekly self-insertions.

Eversense E3 is already available in the U.S. following FDA approval and launch earlier this year. Following the CE Mark approval in Europe the Eversense E3 System will be distributed in Germany, Italy, Spain (including Andorra), the Netherlands, Poland, Switzerland, Norway and Sweden.

Robert Schumm, President at Ascensia Diabetes Care, said, "This approval is an exciting milestone for us as we look forward to bringing Eversense E3 to people with diabetes across Europe. From this next-generation system you can expect the excellent features and benefits that European users currently experience with Eversense XL, but with design improvements that address requests we repeatedly hear from patients and healthcare providers. Our role is to make sure that as many people have access to this innovative product as possible, and efforts are already under way to launch this system in certain European countries in the coming months."

Developed by Senseonics and brought to people with diabetes by Ascensia, the newly approved Eversense E3 CGM System offers patients:

"The features and benefits of this improved system offer people with diabetes unparalleled flexibility, convenience and accuracy," said Elaine Anderson, Head of Eversense CGM Business Unit at Ascensia Diabetes Care. "Choice is key in managing diabetes and we are proud to work alongside our partner Senseonics to bring an outstanding and unique CGM option to patients and healthcare providers across Europe and in the U.S."

People in these markets who are interested in getting started with Eversense XL now can visit http://www.ascensia.com/eversense for more information, and will be among the first to know when Eversense E3 is commercially available.

* There is no glucose data generated when the transmitter is removed.

1 Garg S. et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics 2021; 24(2): 1-9.DOI: 10.1089/dia.2021.0182

SOURCE Ascensia Diabetes Care

See the article here:
ASCENSIA DIABETES CARE ANNOUNCES EUROPEAN APPROVAL OF THE NEXT-GENERATION EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM - PR Newswire

What should diabetes health care professionals consider when treating patients who have sickle cell trait or disease?

World Sickle Cell Day is observed annually on June 19th to raise awareness of sickle cell disease, a group of inherited red blood cell disorders that affect more than 100,000 people in the United States and 20 million people worldwide. For people with sickle cell disease, red blood cells are crescent or sickle shaped and do not bend or move easily, which can block blood flow to the rest of the body and cause repeated infections and episodes of pain.

Hemoglobinopathies (also called hemoglobin variants) are inherited red blood cell conditions that affect hemoglobin, the protein that carries oxygen through the body. One of the most common hemoglobinopathies is hemoglobin S, the sickle cell gene. In a severe form of sickle cell disease, sickle cell anemia, a patient inherits two genes for hemoglobin S.

Patients can also inherit one sickle cell gene and have sickle cell trait, often with no signs or symptoms. This means that many patients are unaware they have sickle cell trait. It is also worth noting that certain populations are more likely to inherit sickle cell traitabout 1 in 13 African Americans and about 1 in 100 Hispanics/Latinos have sickle cell trait.

Sickle Cell Hemoglobinopathies and the A1C Test

For patients who have the sickle cell gene or other hemoglobinopathies, some A1C testing methods for blood glucose may produce unreliable results. An A1C test with falsely high outcomes could lead to the prescription of more aggressive treatments, resulting in increased episodes of hypoglycemia. Conversely, falsely low outcomes could lead to the undertreatment of diabetes.

Laboratories use many different assay methods to measure A1C. Health care professionals should suspect the presence of a hemoglobinopathy when

For more information about hemoglobinopathies and alternative tests to measure blood glucose levels, view NIDDKs health information on Sickle Cell Trait & Other Hemoglobinopathies & Diabetes.

And to learn more about NIDDK Director Dr. Griffin P. Rodgers career researching blood conditions, including sickle cell, watch the videos below.

Link:
Understanding the Link between Diabetes Care and Sickle Cell Disease | NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases...

The number of children being treated at paediatric diabetes units (PDUs) in England and Wales has increased by more than 50% amid a perfect storm of rising obesity levels and the cost of living crisis, health leaders have said.

Diabetes UK said alarming obesity levels among children had led to a concerning climb in the number diagnosed with type 2 diabetes, and predicted that the cost of living crisis could lead to further problems in the years to come.

Data from NHS Digital shows that almost one in seven children start primary school obese a rise of almost 50% in just a year. More than a quarter are obese by the time they finish primary school.

Sign up to First Edition, our free daily newsletter every weekday morning at 7am BST

The high levels of obesity combined with the squeeze on personal finances are creating a perfect storm which risks irreversible harm to the health of young people, Diabetes UK said. It accused the government of letting our children down as it called for concerted action to tackle obesity.

It comes after the governments decision to delay measures to reduce unhealthy eating, weakening its anti-obesity strategy by postponing for a year a ban on buy one, get one free deals for foods high in fat, salt and sugar.

Demand for care for children with type 2 diabetes at paediatric diabetes units across England and Wales has increased by more than 50% in the last five years, according to the Diabetes UK analysis. A total of 973 children with type 2 diabetes were treated in PDUs in 2020-21, up from 621 in 2015-16.

PDUs employ a team of specialists to care for children with type 2 diabetes that can include consultants, nurses and dieticians. The team usually work in a hospital setting, where a child may attend appointments as an outpatient rather than being seen at their GPs surgery. Previous statistics have shown that in England alone, about 1,600 children have been diagnosed with type 2 diabetes.

Diabetes UK said children in the most deprived parts of England and Wales were disproportionately affected by the disease, with four in 10 children and young people with type 2 diabetes living in the poorest areas, compared with only one in 19 from the richest. This is similar to data for childhood obesity prevalence, it said.

The charity said that in light of the additional burden of the cost of living crisis, the poorest children would bear the brunt for decades to come.

Chris Askew, the chief executive of Diabetes UK, said: We are very concerned that this spike in childhood obesity will translate into an even greater increase in children with type 2 diabetes in the coming years, a crisis fuelled by longstanding health inequalities and made worse still by impacts of the cost of living crisis.

Government needs to entirely rethink its commitment to child health. This must start with urgently reversing the decision to backtrack on their obesity strategy commitments and go further still, with bold steps to address childhood obesity and poorer outcomes for children living in poverty in the forthcoming health disparities white paper.

The UK government is letting our children down. With soaring numbers of children now living with obesity, and numbers diagnosed with type 2 diabetes on a very concerning climb, we are facing a perfect storm, which risks irreversible harm to the health of young people.

Continued here:
Child type 2 diabetes referrals in England and Wales jump 50% amid obesity crisis - The Guardian

Sarki AM, Nduka CU, Stranges S, Kandala N-B, Uthman OA: Prevalence of hypertension in low-and middle-income countries: a systematic review and meta-analysis. Medicine 2015, 94(50).

Khan MN, Oldroyd JC, Chowdhury EK, Hossain MB, Rana J, Islam RM: Prevalence, awareness, treatment, and control of hypertension in Bangladesh: Findings from National Demographic and Health Survey, 201718. medRxiv 2021.

Islam R, Khan MN, Oldroyd JC, Rana J, Chowdhury EK, Karim MN, Hossain MB: Prevalence of diabetes and prediabetes among Bangladeshi adults and associated factors: Evidence from the Demographic and Health Survey, 201718. medRxiv 2021.

Patel SA, Ali MK, Alam D, Yan LL, Levitt NS, Bernabe-Ortiz A, Checkley W, Wu Y, Irazola V, Gutierrez L. Obesity and its relation with diabetes and hypertension: a cross-sectional study across 4 geographical regions. Global heart. 2016;11(1):719.

PubMed Article Google Scholar

Say L, Chou D, Gemmill A, Tunalp , Moller A-B, Daniels J, Glmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e32333.

PubMed Article Google Scholar

Mackin ST, Nelson SM, Wild SH, Colhoun HM, Wood R, Lindsay RS. Factors associated with stillbirth in women with diabetes. Diabetologia. 2019;62(10):193847.

CAS PubMed PubMed Central Article Google Scholar

Hedderson MM, Ferrara A. High blood pressure before and during early pregnancy is associated with an increased risk of gestational diabetes mellitus. Diabetes Care. 2008;31(12):23627.

PubMed PubMed Central Article Google Scholar

Pons RS, Rockett FC, de Almeida Rubin B, Oppermann MLR, Bosa VL: Risk factors for gestational diabetes mellitus in a sample of pregnant women diagnosed with the disease. In: Diabetology & metabolic syndrome: 2015: BioMed Central; 2015: 12.

Lu J, Zhang S, Li W, Leng J, Wang L, Liu H, Li W, Zhang C, Qi L, Tuomilehto J. Maternal gestational diabetes is associated with offsprings hypertension. Am J Hypertens. 2019;32(4):33542.

PubMed PubMed Central Article Google Scholar

Miranda JO, Cerqueira RJ, Barros H, Areias JC. Maternal diabetes mellitus as a risk factor for high blood pressure in late childhood: a prospective birth cohort study. Hypertension. 2019;73(1):e17.

CAS PubMed Article Google Scholar

Zhang S, Liu H, Zhang C, Wang L, Li N, Leng J, Li Y, Liu G, Fan X, Yu Z: Maternal glucose during pregnancy and after delivery in women with gestational diabetes mellitus on overweight status of their children. BioMed research international 2015, 2015.

Tam WH, Ma RCW, Ozaki R, Li AM, Chan MHM, Yuen LY, Lao TTH, Yang X, Ho CS, Tutino GE. In utero exposure to maternal hyperglycemia increases childhood cardiometabolic risk in offspring. Diabetes Care. 2017;40(5):67986.

CAS PubMed PubMed Central Article Google Scholar

Hillier TA, Pedula KL, Schmidt MM, Mullen JA, Charles M-A, Pettitt DJ. Childhood obesity and metabolic imprinting: the ongoing effects of maternal hyperglycemia. Diabetes Care. 2007;30(9):228792.

PubMed Article Google Scholar

Association AD. Management of diabetes in pregnancy: standards of medical care in diabetes2019. Diabetes Care. 2019;42(Supplement 1):S16572.

Article Google Scholar

Chuang CH, Chase GA, Bensyl DM, Weisman CS. Contraceptive use by diabetic and obese women. Womens Health Issues. 2005;15(4):16773.

PubMed Article Google Scholar

Perritt JB, Burke A, Jamshidli R, Wang J, Fox M. Contraception counseling, pregnancy intention and contraception use in women with medical problems: an analysis of data from the Maryland Pregnancy Risk Assessment Monitoring System (PRAMS). Contraception. 2013;88(2):2638.

PubMed Article Google Scholar

Vahratian A, Barber JS, Lawrence JM, Kim C. Family-planning practices among women with diabetes and overweight and obese women in the 2002 National Survey For Family Growth. Diabetes Care. 2009;32(6):102631.

PubMed PubMed Central Article Google Scholar

Harris M, Egan N, Forder PM, Bateson D, Sverdlov AL, Murphy VE, Loxton D: Patterns of contraceptive use among young Australian women with chronic disease: findings from a prospective cohort study. 2021.

Nojomi M, Morrovatdar N, Davoudi F, Hosseini S. Contraceptive use by Iranian women with hypertension, diabetes or obesity. EMHJ-Eastern Mediterranean Health J. 2013;19(7):63843.

CAS Article Google Scholar

Mekonnen TT, Woldeyohannes SM, Yigzaw T. Contraceptive use in women with hypertension and diabetes: cross-sectional study in northwest Ethiopia. Int J Womens Health. 2015;7:957.

Google Scholar

Afshari M, Alizadeh-Navaei R, Moosazadeh M. Oral contraceptives and hypertension in women: results of the enrolment phase of Tabari Cohort Study. BMC Womens Health. 2021;21(1):17.

Article Google Scholar

Robinson A, Nwolise C, Shawe J. Contraception for women with diabetes: challenges and solutions. Open Access J Contracept. 2016;7:11.

PubMed PubMed Central Article Google Scholar

KHAN MN: Effects of Unintended Pregnancy on Maternal Healthcare Services Use in Bangladesh. Faculty of Health and Medicine, School of Medicine and Public Health, The; 2020.

Khan MN, Harris M, Loxton D. Modern contraceptive use following an unplanned birth in Bangladesh: an analysis of national survey data. Int Perspect Sex Reprod Health. 2020;46:7787.

PubMed Article Google Scholar

Khan MN, Islam MM. Exploring rise of pregnancy in Bangladesh resulting from contraceptive failure. Sci Rep. 2022;12(1):110.

Article Google Scholar

Bishwajit G, Tang S, Yaya S, Feng Z. Unmet need for contraception and its association with unintended pregnancy in Bangladesh. BMC Pregnancy Childbirth. 2017;17(1):19.

Article Google Scholar

Huda FA, Chowdhuri S, Robertson Y, Islam N, Sarker BK, Azmi AJ, Reichenbach L: Understanding unintended pregnancy in Bangladesh: country profile report. 2013.

NIPORT MaA, ICF International, : Bangladesh Demographic and Health Survey, 2017/18. In. NIPORT, Mitra & Associates and ICF International, Dhaka, Bangladesh and Calverton, MD, USA2013.; 2020.

Greydanus DE, Omar HA, Tsitsika A: Obesity and contraception. 2009.

WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England). 2004;363(9403):15763.

Article Google Scholar

Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3(1):113.

Article Google Scholar

Tamhane AR, Westfall AO, Burkholder GA, Cutter GR. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. Stat Med. 2016;35(30):57305.

PubMed PubMed Central Google Scholar

O'Connell AA, McCoach DB: Multilevel modeling of educational data: IAP; 2008.

Von Elm E, Altman DG, Egger M, Pocock SJ, Gtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ. 2007;85:86772.

Article Google Scholar

World Health Organization: Maternal mortality. In. Geneva, Switzarland The World Health Organization 2021.

Buchanan TA, Xiang AH, Page KA. Gestational diabetes mellitus: risks and management during and after pregnancy. Nat Rev Endocrinol. 2012;8(11):639.

CAS PubMed PubMed Central Article Google Scholar

Khan MN, Islam MM, Akter S: Availability and readiness of healthcare facilities and their effects on long-acting modern contraception use in Bangladesh: Analysis of linked data. medRxiv 2021.

Beaglehole R, Epping-Jordan J, Patel V, Chopra M, Ebrahim S, Kidd M, Haines A. Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. The Lancet. 2008;372(9642):9409.

Article Google Scholar

National Institute of Population Research and Training (NIPORT) and ICF: Bangladesh Health Facility Survey 2017. In. Dhaka, Bangladesh: NIPORT, ACPR, and ICF.; 2019.

Ahmad A, Oparil S. Hypertension in women: recent advances and lingering questions. Hypertension. 2017;70(1):1926.

CAS PubMed Article Google Scholar

Schwarz EB, Postlethwaite D, Hung Y-Y, Lantzman E, Armstrong MA, Horberg MA. Provision of contraceptive services to women with diabetes mellitus. J Gen Intern Med. 2012;27(2):196201.

PubMed Article Google Scholar

Marshall CJ, Huma Z, Deardorff J, Britton LE. Prepregnancy counseling among US Women with diabetes and hypertension, 20162018. Am J Prev Med. 2021;61(4):52936.

PubMed Article Google Scholar

Pallardo L, Cano A, Cristobal I, Blanco M, Lozano M, Lete I: Hormonal contraception and diabetes. Clinical Medicine Insights: Women's Health 2012, 5:CMWH. S9934.

Endriyas M, Eshete A, Mekonnen E, Misganaw T, Shiferaw M. Where we should focus? Myths and misconceptions of long acting contraceptives in Southern Nations, Nationalities and Peoples Region, Ethiopia: qualitative study. BMC Pregnancy Childbirth. 2018;18(1):16.

Article Google Scholar

Medical News Today: Debunking common birth control myths. In.; 2020.

Ochako R, Mbondo M, Aloo S, Kaimenyi S, Thompson R, Temmerman M, Kays M. Barriers to modern contraceptive methods uptake among young women in Kenya: a qualitative study. BMC Public Health. 2015;15(1):19.

Article Google Scholar

Kersten I, Lange AE, Haas JP, Fusch C, Lode H, Hoffmann W, Thyrian JR. Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNiP-study. BMC Pregnancy Childbirth. 2014;14(1):113.

Article Google Scholar

Lykens JE, Broecker JE. Contraceptive options for women with metabolic syndrome. Osteopathic Family Physician. 2011;3(3):8898.

Article Google Scholar

Lathrop E, Jatlaoui T. Contraception for women with chronic medical conditions: an evidence-based approach. Clin Obstet Gynecol. 2014;57(4):67481.

PubMed Article Google Scholar

Adongo PB. Tabong PT-N, Azongo TB, Phillips JF, Sheff MC, Stone AE, Tapsoba P: A comparative qualitative study of misconceptions associated with contraceptive use in southern and northern Ghana. Front Public Health. 2014;2:137.

PubMed PubMed Central Article Google Scholar

Originally posted here:
Pattern of contraceptive use among reproductive-aged women with diabetes and/or hypertension: findings from Bangladesh Demographic and Health Survey -...

LUBBOCK, Texas (PRESS RELEASE) The following is a press release from Covenant Health:

Covenant Childrens will host a free Diabetes Camp called New Beginnings for children ages 5-14 who have diabetes. The camp will be July 13-16, 2022, from 9 a.m. to 4 p.m., with each day at a different location in Lubbock. Locations will include the Science Spectrum, Main Event, YWCA and Spirit Ranch.

Due to the recent loss of the local American Diabetes Association chapter in the area, Covenant Childrens and Covenant Health Foundation recognized the need to replace the annual diabetes camp that used to be held by the organization.

We recognize the value and impact that a camp for children with diabetes holds. Kids with diabetes, and their families, need to know and see they are not alone, said Brittny Ayola, Covenant Childrens PICU nurse manager and diabetes education program coordinator.

The camp is free and open to all children in Lubbock and the surrounding area. Lunches, snacks, t-shirt and activities are covered; however, housing is not provided for attendees from out of town. Children will need to bring their own diabetes supplies.

As a diabetic herself, Ayola said when she was growing up, there were no camps in Lubbock, so she had to go out of town for similar experiences. Ayola said it can feel very isolating to have a chronic condition that takes daily management and being able to do normal activities with other children who also have diabetes can have a vast impact.

There will be medical professionals who have had diabetes training to oversee safety and give parents peace of mind while their child builds friendships and enjoys the camp. Through the day campers will do carb counts, take insulin and check blood sugar together.

On the last day of camp, there will be vendor booths for parents and families to learn more about diabetes technology, products and medications.

There are still spots available. The deadline to register is July 1, or when spots are full. Parents can sign up their child through the form at the following link: https://bit.ly/39tVGH5

If children with diabetes over the age of 15 are interested in participating, there are opportunities to help as a junior counselor or counselor. Contact Brittny Ayola at AYOLABS2@covhs.org or (806) 786-2968 for more information.

About Covenant Health:

Covenant Childrens is the only independently licensed, freestanding, childrens hospital in West Texas and eastern New Mexico and is one of only eight members of the Childrens Hospital Association of Texas and is the only one in our region.

As a faith-based health care system, it is Covenant Healths vision to create Health for a Better World. As the Best Hospital in the Panhandle Plains region as voted by U.S. News and World Report, Covenant Health has consistently provided exceptional health care to West Texas, and eastern New Mexico for more than 100 years. Our clinically integrated health network of eight hospitals, and more than 6,000 caregivers allows us to provide our patients with better access to care using more innovative technology and procedures, while focusing on new age approaches to health care like education and preventative medicine. To learn more about Covenant Health, please visit covenanthealth.org or our Facebook, LinkedIn, or Twitter, pages.

(Press release from Covenant Health)

See the rest here:
Covenant Childrens to host diabetes camp in July - KLBK | KAMC | EverythingLubbock.com

CASES of diabetes are on the up and it's estimated around 13.6million Brits are at risk.

While key symptoms usually include extreme thirst and an increased need to urinate, there could also be signs on your skin.

1

Diabetes is a serious condition in which the level of glucose in your body is too high.

There are two types, with the main difference being that type 1 diabetes is a genetic condition, with type 2 mainly being down to lifestyle choices.

But both are as serious as each other and can lead to serious health complications.

With that in mind, it's important to know how the illness could show up in your skin.

Chartered chemist, Bruce Green said that diabetic skin can be similar to skin that has prematurely aged.

"The skin changing process is Glycation. A process where proteins and sugars are cross-linked to advanced glycation end products (age) there is a negative impact on the elasticity of the skin, when collagen and elastin are stiffened," he said.

He explained skin problems are more likely amongst diabeticsbecause of reduced circulation and reduced sensitivity of nerves.

In addition, Bruce, who is the founder of diabetic skincare range, SOS Serum Skincare said there are six key warning signs you need to be aware of.

Signs to look out for on the skin are:

However, these aren't the only signs you need to be aware of.

The NHS recommends that you see a doctor if you're feeling very thirsty and you're peeing more frequently than usual - especially at night.

Other key signs of diabetes include feeling very tired, weight loss and a loss of muscle bulk and blurred vision.

When it comes to your skin, the NHS says that itching around the penis or vagina or experiencing cuts or wounds that heal slowly are also common signs - all of which you should seek medical attention for.

If you are diabetic - then it's key that you look after your skin.

Bruce said that when it comes to cleaning yourself, you should use a mild soap-free, alcohol free substance.

You need to make sure that you wipe it off and dry off properly - as damp skin can cause irritation.

When it comes to keeping your skin soft and supple, the skin guru said you should also use a high quality moisturiser with a minimum SPF of 30.

"Avoid perfumed products and petrochemical ingredients and look for a short ingredient list, he advised.

He also suggested that when you can, you should try and wear 100 per cent cotton.

"This allows a healthy through flow of air and helps to reduce localised perspiration," he added.

We pay for your stories!

Do you have a story for The Sun news desk?

Here is the original post:
Diabetes warning: The 6 signs on your SKIN that can be a sign of life-threatening disease... - The Sun

NEW YORK, Dec. 3, 2021 /PRNewswire/ -- JDRF, the leading global funder of type 1 diabetes (T1D) research, proudly announces the relaunch of Rufus, the Bear with Diabetes .

The newly redesigned bear now features special patches to interact within Rufus' world on the new companion mobile application "Rufus the Bear with Diabetes," made possible by the JDRF Beyond Type 1 Alliance, which features educational and fun games to teach children about life with diabetes. Through the app, children can help Rufus manage his diabetes and gain hands-on practice with diabetes management essentials like counting cards, monitoring blood sugar, and dosing with insulin.

"For more than 25 years, Rufus has been one of the most requested support items for children with T1D," said Kristin Horowitz, Senior Manager of Community Engagement at JDRF. "Rufus' new upgrades now match the most up-to-date T1D management options and will help so many newly diagnosed families easily learn the basics of day-to-day diabetes care in a fun way."

In the app, users will get to utilize Rufus's virtual diabetes toolkit, which includes a glucometer, insulin pen, pump, and a CGM, guiding them to make healthy choices in the kitchen to learn about the impact of carbs and how to identify them. But the fun doesn't stop there, as users can follow the adventures of Rufus as he trains for the All-Star Game in 21 interactive e-books on the app. In addition, the interactive learning curriculum co-designed by doctors, educators, and families include fun and educational content.

"I am excited to see the progression of Rufus," said Carol Cramer, creator of Rufus the Bear. "When I put together the first Rufus bear I wanted to provide my son with an object of comfort to help navigate his new normal, but little did I know through connecting with JDRF and other T1D families there was a widespread need for a comforting companion. Over the years, I have seen Rufus help families through the hardest times and I am extremely proud of the continued work of JDRF to ensure so many children receive their new diabetes best friend."

Rufus is available to newly diagnosed families through the Bag of Hope program and on the JDRF store https://shop.jdrf.org/product/JDRF-Rufus.

The app Rufus the Bear with Diabetes is available on Google Play, Apple App Store and the Amazon App Store.

About T1DType 1 diabetes (T1D) is an autoimmune disease in which a person's pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the Relpancreas, called beta cells. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. Its onset has nothing to do with diet or lifestyle. There is nothing you can do to prevent T1D, andat presentnothing you can do to get rid of it.

About JDRFJDRF's mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).

About Beyond Type 1

Beyond Type 1 is a nonprofit organization changing what it means to live with diabetes. Through platforms, programs, resources, and grants, Beyond Type 1 is uniting the global diabetes community and providing solutions to improve lives today. Founded in 2015 with a focus on education, advocacy and the path to a cure for Type 1 diabetes, Beyond Type 1 has grown to also include programs for those with Type 2 diabetes. A new model of philanthropy, Beyond Type 1 aims to change what it means to live with chronic illness. For more information, visit beyondtype1.org or follow @beyondtype1 on social media.

View original content to download multimedia: https://www.prnewswire.com/news-releases/jdrf-announces-the-relaunch-of-rufus-the-bear-with-diabetes-301437309.html

SOURCE JDRF

Continue reading here:
http://www.thestreet.com

When you think of diabetes, you probably think of glucose. Insulin. High blood pressure. Your pancreas.

But what about your eyes?

Although they may not be the first thing you think of when it comes to diabetes, your vision can be heavily impacted, and permanently damaged by it, with one in three people aged 40 or older with diabetes showing signs of diabetic retinopathy, according to the National Institute of Diabetes and Digestive and Kidney Disease.

MORE FROM MICHIGAN: Sign up for our weekly newsletter

Your eyes are an important window into the health of the rest of your body, said Julie Rosenthal, M.D., M.S., an ophthalmologist at the Kellogg Eye Center who specializes in diseases of the retina and vitreous. Below, Rosenthal shares essential information about the disease and eye health.

1. At first, the eye damage from diabetes may not be noticeable

Often, Rosenthal explains, there arent clear early warning signs that you have diabetic eye disease, that its developing, or even progressing.

And the longer you have diabetes, the greater the risk you have of it affecting your eyes.

Early changes can include bleeding within the retina, which may not affect your vision at first. At any stage, you can develop swelling in the macula, which often leads to blurred central vision, known as macular edema, said Rosenthal. The macula is where you have your sweet spot of vision. It's what helps you recognize faces, read and see objects up close.

As your diabetes advances to the later stages, the blood flow to the retina can decrease, depriving your retina of oxygen and nutrition, recruiting new blood vessels, called neovascularization, one of the hallmarks of a condition called diabetic retinopathy.

While those new blood vessels sound like a really great solution to not getting enough nutrients and oxygen, they're not good blood vessels, said Rosenthal. And, if left untreated, they can lead to vision loss."

2. If left untreated, diabetic retinopathy could cause irreversible vision loss

Diabetic retinopathy has two stages:

Non-proliferative diabetic retinopathy, or NPDR: The retina can have spots of bleeding, areas where blood flow is disrupted called cotton wool spots, and fatty tissues that leak from the blood vessels into the retina. This can result in serious vision loss if left untreated.

Proliferative diabetic retinopathy (PDR): The more advanced form of the disease develops when new blood vessels form on the retina by way of neovascularization. The blood vessels, which break easily and are extremely fragile, can lead to bleeding within the eye, causing cloudy vision. Left untreated, the disease can result in retinal tears or detachments, both which can severely damage your vision.

Macular edema can happen at either of these stages.

3. Luckily, there are treatment options available for diabetic retinopathy

According to Rosenthal, the gold standard for PDR is a laser treatment.

When your eye is not receiving great blood flow, it sends a signal to bring these new blood vessels, said Rosenthal. Were trying to stop that signal from being sent by putting laser in those areas.

At Kellogg, laser surgery is considered the mainstay of treatment for proliferative diabetic retinopathy. Most of us at Kellogg, and many other retina specialists, feel that its probably the best option, said Rosenthal.

Another treatment option involves medicine injections into the eye, which can sometimes treat the new blood vessels being formed.

Although sometimes these new blood vessels can be treated with these injections, the treatment is temporary and needs to be repeated, often monthly, Rosenthal said.

The injections are a great treatment for macular edema, however, and can help improve your vision if you have this.

4. Good health maintenance and consistent doctor visits are key in preventing severe disease

Since these eye complications stem from an underlying, chronic disease, the problem must be attacked at the root by regulating your blood sugar, blood pressure and cholesterol with your primary care provider.

But Rosenthals biggest piece of advice? Visit an eye doctor yearly.

You might not notice any problems during the earlier stages, so its important to get your eyes examined regularly, said Rosenthal. If we can detect the issue early, we have a much better chance of preventing irreversible vision loss and the later stages of the disease.

She adds that warning signs of advancing diabetic eye disease may include new floaters, decreased vision or spots in your vision.

As a patient with diabetes, you may already feel as if your schedule is filled with medical appointments and its difficult to make time for another. However, eye health is critical, and vision loss from diabetes is preventable with timely interventions.

Like Podcasts? Add the Michigan Medicine News Break oniTunes or anywhere you listen to podcasts.

Follow this link:
Diabetes and your eyes: 4 things to know - University of Michigan Health System News